Señales en vivo de NRSN | Maximiza tus Ganancias con Getagraph.com

VENDER 120994 min ago

@ $1.320

Emitido: 14 feb 2024 @ 12:31

Retorno: -6.82%

Live Chart Being Loaded With Signals

Commentary (8 may 2024 @ 14:00):

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases...

Stats
Volumen de hoy	45 422.00
Volumen promedio	296 931
Capitalización de mercado	21.32M
EPS	$0 ( 2024-04-04 )
Próxima fecha de ganancias	( $-0.190 ) 2024-05-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.480
ATR14	$0.0220 (1.79%)

Volumen Correlación

Largo: -0.05 (neutral)

Corto: 0.58 (weak)

Signal:(42.701) Neutral

NeuroSense Therapeutics Correlación

10 Correlaciones Más Positivas
TARA	0.944
BNIXU	0.931
CREX	0.931
VSMV	0.925
KYMR	0.924
UNCY	0.921
NICE	0.919
KNSL	0.917
MRUS	0.913
LECO	0.913

10 Correlaciones Más Negativas
DSWL	-0.892
CRCT	-0.892
RTPY	-0.885
OSTK	-0.882
BLKB	-0.881
SGML	-0.878
SRNGW	-0.878
DPRO	-0.875
BIOL	-0.872
BSGM	-0.871

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NeuroSense Therapeutics Correlación - Moneda/Commodity

-0.28
( neutral )

-0.13
( neutral )

0.00
( neutral )

-0.28
( neutral )

0.01
( neutral )

-0.61
( weak negative )

NeuroSense Therapeutics Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-97 000.00 (0.00 %)
EPS:	$-0.830

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-97 000.00 (0.00 %)
EPS:	$-0.830

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-89 000.00 (0.00 %)
EPS:	$-0.970

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.650

Financial Reports:

No articles found.

NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.